SMMT - Summit pares gains as 'China-only' trial beats Merck's Keytruda
2024-05-31 08:59:26 ET
More on Akeso, Merck, etc.
- Merck Stock: Still Discounted To Graham P/E
- Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript)
- Merck: The Worst Has Been Avoided (Rating Upgrade)
- Dividend Roundup: Meta Platforms, Merck, Cigna, Halliburton, and more
- Summit lead asset beats Merck’s Keytruda in a first in lung cancer